The treatment landscape for early-stage melanoma has seen an exciting shift with the advent of immunotherapy in the adjuvant setting for patients who have had early-stage tumors resected. In this on-demand video, join an expert-led discussion of the latest clinical data, guideline recommendations, adverse event management, and multidisciplinary biomarker-guided treatment planning. Don’t miss the expert perspectives on engaging patients in shared-decision making, and integration of adjuvant treatment into clinical practice in early-stage melanoma.Through this educational activity, you have the opportunity to earn a maximum of 2.5 CE credits in total. To achieve this, you can complete the PRIME on-demand video to earn 0.5 CE credits. Additionally, if you choose to engage with the SynopsiMedEd Related Evidence articles, you can earn an extra 2.0 CE credits. If you decide not to engage with these articles, you can still claim partial credit based on your level of participation.Total Possible Credits: 2.0 CE Credits from PRIME On-Demand Video: 0.5 CE Credits from SynopsiMedEd Related Evidence: 1.5 CE This activity is delivered in partnership with the Melanoma Research Alliance.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancing-evidence-based-immunotherapy-treatment-early-stage-melanoma
- Start Date: 2024-09-13 05:00:00
- End Date: 2024-09-13 05:00:00
- Credit Details: IPCE Credits: 2.0 hours
AAPA Category 1 Credit™️: 2.0 hours
AMA PRA Category 1 Credit™️: 2.0 hours
Nursing: 2.0 hours
Pharmacy: 2.0 hours - Commercial Support: Source: Merck (Any division) - Amount: 33333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all